S'abonner

The current and future global burden of cancer among adolescents and young adults: a population-based study - 03/12/24

Doi : 10.1016/S1470-2045(24)00523-0 
Taylor Hughes, MSc a, Andrew Harper, MSc c, Sumit Gupta, PhD d, A Lindsay Frazier, ProfMD e, Winette T A van der Graaf, ProfMD f, Florencia Moreno, MD g, Adedayo Joseph, MD h, i, Miranda M Fidler-Benaoudia, PhD a, b, c,
a Department of Oncology, University of Calgary, Calgary, AB, Canada 
b Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada 
c Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Arthur Child Cancer Centre, Calgary, AB, Canada 
d Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada 
e Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA 
f Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands 
g Argentinian Oncopediatric Registry, National Cancer Institute, Health Ministry, Buenos Aires City, Argentina 
h NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Lagos, Nigeria 
i Department of Radiation Biology, Radiodiagnosis and Radiotherapy, College of Medicine, University of Lagos, Lagos, Nigeria 

* Correspondence to: Dr Miranda Fidler-Benaoudia, Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Arthur Child Cancer Centre, Calgary, AB T2N 5G2, Canada Department of Cancer Epidemiology and Prevention Research Cancer Care Alberta Alberta Health Services Arthur Child Cancer Centre Calgary AB T2N 5G2 Canada

Summary

Background

Compared with children and older adults, the burden of cancer in adolescents and young adults (ages 15–39) is understudied. We aimed to quantify the global burden of adolescent and young adult cancer in 2022 and 2050, and explore patterns in incidence, mortality, and case fatality.

Methods

In this population-based study, we used the GLOBOCAN database to quantify the number of new cases and cancer-related deaths, and corresponding age-standardised incidence and mortality rates (ASRs; per 100 000 people aged 15–39 years), in adolescents and young adults. Estimates were quantified for all cancers combined, excluding non-melanoma skin cancer, and 33 specific cancer types. Case fatality was estimated using mortality-to-incidence ratios. Overall and sex-specific estimates were calculated at the world, regional, human development index (HDI), and income level. We estimated the future cancer burden by applying the GLOBOCAN 2022 rates to sex-specific demographic projections for the year 2050 using the UN World Population Prospects 2019 revision.

Findings

An estimated 1 300 196 cases and 377 621 cancer-related deaths occurred in adolescents and young adults in 2022. Incidence ASRs were 1·9-times higher and mortality ASRs were 1·2-times higher in females than in males (incidence ASR 52·9 vs 28·3; mortality ASR 13·1 vs 10·6). Although the incidence ASR was highest in the high-income countries, the mortality ASR was highest in the low-income countries; as a result, case fatality ranged from 12% in high-income settings to 57% in low-income settings. Of the 33 cancer types included in our analyses, breast or cervical cancer was the most frequently diagnosed cancer and cause of cancer-related death in 163 and 93 countries, respectively; incidence and mortality also varied the most by region for these cancers. Finally, the adolescent and young adult cancer burden globally is projected to increase by about 12% from 2022 to 2050, albeit with declines of 10·7% projected in very high HDI countries. The increase is expected to overwhelmingly impact low HDI settings, where the burden of both cancer cases and deaths is projected to double (a 102·3% increase).

Interpretation

Although the adolescent and young adult cancer burden incidence is highest in the most developed settings, transitioning countries have the poorest outcomes and will face the greatest increases in burden by 2050. These findings act as a reference to the global adolescent and young adult cancer community to inform cancer control priorities and decrease global inequities.

Funding

None.

Le texte complet de cet article est disponible en PDF.

Plan


© 2024  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 25 - N° 12

P. 1614-1624 - décembre 2024 Retour au numéro
Article précédent Article précédent
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
  • Pier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, Stefan K Barta, Kenji Ishitsuka, Raul Córdoba, Shigeru Kusumoto, Emmanuel Bachy, Kate Cwynarski, Giuseppe Gritti, Anca Prica, Eric Jacobsen, Tatyana Feldman, Yann Guillermin, Daisuke Ennishi, Dok Hyun Yoon, Eva Domingo Domenech, Jasmine Zain, Jie Wang, Jin Seok Kim, Marjolein van der Poel, Jin Jin, Sutan Wu, Yang Chen, Takaya Moriyama, Ai Inoue, Keiko Nakajima, Steven M Horwitz
| Article suivant Article suivant
  • Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial
  • Sujay Vora, Deanna Pafundi, Molly Voss, Matthew Buras, Jonathan Ashman, Bernard R Bendok, William Breen, Leland Hu, Sani Kizilbash, Nadia Laack, Wei Liu, Anita Mahajan, Maciej Mrugala, Alyx Porter, Michael Ruff, Terence Sio, Joon Uhm, Ming Yang, Debra Brinkmann, Paul Brown

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.